Predictors of talc pleurodesis outcome in patients with malignant pleural effusions

被引:29
作者
Yildirim, Huseyin [1 ]
Metintas, Muzaffer [1 ]
Ak, Guentuelue [1 ]
Metintas, Selma [2 ]
Erginel, Sinan [1 ]
机构
[1] Osmangazi Univ, Fac Med, Dept Chest Dis, TR-26480 Meselik, Eskisehir, Turkey
[2] Osmangazi Univ, Fac Med, Dept Publ Hlth, Eskisehir, Turkey
关键词
Malignant pleural effusions; Talc; Pleurodesis; pH; ADA;
D O I
10.1016/j.lungcan.2008.02.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Chemical pleurodesis is an accepted palliative therapy for patients with recurrent, symptomatic, malignant pleural effusions (MPE). The purpose of the study was to determine the factors that have an effect on successful pleurodesis for MPE. Patients and interventions: Eighty-four consecutive patients with biopsy-proven malignant pleural disease and recurrent, symptomatic MPE were eligible to participate in this study. Five grams of talc mixed in 150ml of normal saline were administered via tube thoracostomy or small-bore catheters after complete drainage of the pleural effusion. Results: Seven patients did not return for their 30-day follow-up visit and were excluded from further analysis. Successful pleurodesis was achieved in 63 of 77 eligible patients (81.8%) with MPE. In the univariate analysis, female gender, Karnofsky performance status, pleural fluid pH, cholesterol, and adenosine deaminase level showed a significant association with the probability of success. Multivariate Logistic regression analysis showed that pleural fluid pH and ADA levels were independent predictors of talc pleurodesis outcome. Conclusion: Our results show that pleurodesis using talc as the sclerosing agent is a simple and acceptable procedure with high efficacy for controlling MPE, especially when used in appropriate patients. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 14 条
[1]   Thoracoscopic talc poudrage in malignant pleural effusions [J].
Aelony, Y ;
King, RR ;
Boutin, C .
CHEST, 1998, 113 (04) :1007-1012
[2]   Management of malignant pleural effusions [J].
Antony, VB ;
Loddenkemper, R ;
Astoul, P ;
Boutin, C ;
Goldstraw, P ;
Hott, J ;
Panadero, FR ;
Sahn, SA .
EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (02) :402-419
[3]   Predicting survival in patients with recurrent symptomatic malignant pleural effusions - An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease [J].
Burrows, CM ;
Mathews, C ;
Colt, HG .
CHEST, 2000, 117 (01) :73-78
[4]   Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion [J].
Dresler, CM ;
Olak, J ;
Herndon, JE ;
Richards, WG ;
Scalzetti, E ;
Fleishman, SB ;
Kernstine, KH ;
Demmy, T ;
Jablons, DM ;
Kohman, L ;
Daniel, TM ;
Haasler, GB ;
Sugarbaker, DJ .
CHEST, 2005, 127 (03) :909-915
[5]  
Giusti G, 1983, METHODS ENZYME ANAL
[6]   Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: A randomised trial [J].
Goodman, Anna ;
Davies, Christopher W. H. .
LUNG CANCER, 2006, 54 (01) :51-55
[7]   Pleural fluid on as a predictor of pleurodesis failure - Analysis of primary data [J].
Heffner, JE ;
Nietert, PJ ;
Barbieri, C .
CHEST, 2000, 117 (01) :87-95
[8]   Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis [J].
Mager, HJ ;
Maesen, B ;
Verzijlbergen, F ;
Schramel, F .
LUNG CANCER, 2002, 36 (01) :77-81
[9]   Malignant pleural effusion:: Prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases [J].
Martínez-Moragón, E ;
Aparicio, J ;
Sanchis, J ;
Menéndez, R ;
Rogado, MC ;
Sanchis, F .
RESPIRATION, 1998, 65 (02) :108-113
[10]  
*PLEUR DIS GROUP, 2003, THORAX, V58, P29